HPV infections: Can they be eradicated using nanotechnology?

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 2, 2012, Pages 131-135

  Foldvari, Marianna ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Cervical cancer; Human papillomavirus; Nanotechnology; Topical interferon alpha; Vaccine

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; IMIQUIMOD; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

ANTIVIRAL THERAPY; CONDYLOMA ACUMINATUM; CRYOSURGERY; HUMAN; NANOTECHNOLOGY; NEOPLASM; NON INVASIVE PROCEDURE; NOTE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT;

ADMINISTRATION, TOPICAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DRUG DELIVERY SYSTEMS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERFERON-ALPHA; NANOPARTICLES; NANOTECHNOLOGY; PAPILLOMAVIRUS VACCINES;

HUMAN PAPILLOMAVIRUS;

EID: 84855849064     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.11.006     Document Type: Note

References (25)

1. Burchell A.N., Winer R.L., de Sanjose S., Franco E.L. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24(Suppl 3):S3/52-61.
2. Pagliusi S.R., Dillner J., Pawlita M., Quint W.G., Wheeler C.M., Ferguson M. Chapter 23: international standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 2006, 24(Suppl 3):S3/193-200.
3. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57:7-28.
4. Barzon L., Militello V., Pagni S., Franchin E., Dal Bello F., Mengoli C., Palu G. Distribution of human papillomavirus types in the anogenital tract of females and males. J Med Virol 2010, 82:1424-1430.
5. Schiller J.T., Day P.M., Kines R.C. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010, 118:S12-S17.
6. Woodman C.B., Collins S.I., Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007, 7:11-22.
7. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
8. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
9. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009, 384:260-265.
10. Ferenczy A., Braun L., Shah K.V. Human papillomavirus (HPV) in condylomatous lesions of cervix. Am J Surg Pathol 1981, 5:661-670.
11. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197:346-355.
12. Kaufmannand A.M., Schneider A. New paradigm for prevention of cervical cancer. Eur J Obstet Gynecol Reprod Biol 2007, 130:25-29.
13. Shi L., Sings H.L., Bryan J.T., Wang B., Wang Y., Mach H., et al. Gardasil: prophylactic human papillomavirus vaccine development-from bench top to bed-side. Clin Pharmacol Ther 2007, 81:259-264.
14. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59:626-629.
15. Deschuyteneer M., Elouahabi A., Plainchamp D., Plisnier M., Soete D., Corazza Y., et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010, 6:407-419.
16. Chen X.S., Garcea R.L., Goldberg I., Casini G., Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000, 5:557-567.
17. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180-12184.
18. Widdice L.E., Bernstein D.I., Leonard A.C., Marsolo K.A., Kahn J.A. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics 2011, 127:77-84.
19. Beard K. Reducing the rate of cervical cancer: ethical challenges in public health. J Natl Black Nurses Assoc 2010, 21:39-43.
20. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2009. MMWR Morb Mortal Wkly Rep 2010, 59:1018-1023.
21. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59:630-632.
22. Ma B., Xu Y., Hung C.F., Wu T.C. HPV and therapeutic vaccines: Where are we in 2010?. Curr Cancer Ther Rev 2010, 6:81-103.
23. Foldvari M., Badea I., Kumar P., Wettig S., Batta R., King M.J., et al. Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv 2011, 8:307-319.
24. Foldvari M. Biphasic vesicles: a novel topical drug delivery system. J Biomed Nanotechnol 2010, 6:543-557.
25. Foldvari M., Badea I., Wettig S., Baboolal D., Kumar P., Creagh A.L., et al. Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol Pharm 2010, 7:751-762.